Evidence map›Paper›PMID 42819228›Full record

ArticleOpen forum infectious diseases2026

Changes in Three-Dimensional Volumetric Liver Fat Fraction after Cure of Chronic Hepatitis C Infection With Direct-Acting Antivirals.

Jessie Torgersen, Craig W Newcomb, Dean M Carbonari, Shanae M Smith, Katherine L Brecker, Chamith S Rajapakse, Brandon C Jones, Christiana Cottrell, Rasleen Grewal, Jennifer C Price and 7 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jessie TorgersenDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-7861-1421
Craig W NewcombDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Real-world Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Dean M CarbonariDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Real-world Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0310-270X
Shanae M SmithDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Real-world Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Katherine L BreckerDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Real-world Effectiveness and Safety of Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Chamith S RajapakseDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-9247-833X
Brandon C JonesDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-9352-5521
Christiana CottrellDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Rasleen GrewalDepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jennifer C PriceDepartment of Medicine, University of California, SanFrancisco School of Medicine, San Francisco, California, USA.
Joshua F BakerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0799-7563
Jay R KostmanPhiladelphia FIGHT, Philadelphia, Pennsylvania, USA.
Stacey TrooskinMazzoni Center, Philadelphia, Pennsylvania, USA.
Rebecca A HubbardDepartment of Biostatistics, Brown University School of Public Health, Providence, Rhode Island, USA.ORCID https://orcid.org/0000-0003-0879-0994
Babette S ZemelDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-6164-7348
Mary B LeonardDepartment of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.ORCID https://orcid.org/0000-0002-8972-6582
Vincent Lo ReDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-7955-0600

Funding

Phenotypic Diversity in COVID-19UL1TR001878 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2016 to 2025
$102.4M
Changes in Bone Quality, Sarcopenia and Fat Distribution in HIV/HCV Patients after HCV TherapyR01AI136626 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LO RE, VINCENT · 2018 to 2022
$4.0M
Use of Deep Learning Algorithms to Enable Evaluation of the Determinants and Outcomes of Hepatic Steatosis, by HIV StatusK08DK132977 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Jessie Torgersen · 2022 to 2026
$840k
NCATS NIH HHS UL1 TR001878NIAID NIH HHS R01 AI136626NIDDK NIH HHS K08 DK132977
6 · The paper itself

Abstract

Background: It remains unclear if cure of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) leads to change in liver fat fraction and if this change differs from people without HCV observed over similar time. We evaluated the change in three-dimensional volumetric liver fat fraction by magnetic resonance imaging (MRI) prior to DAA treatment and 18 months following initiation and compared changes in uninfected controls over 18 months. Methods: We conducted a cohort study of 35 participants who initiated DAAs and achieved cure and 42 without HCV infection as controls. At enrollment and 18 months later, participants had measurements of height, body weight, and three-dimensional volumetric liver fat fraction and cross-sectional area of abdominal subcutaneous and visceral adipose tissue by MRI. Multivariable linear regression was used to estimate group differences in mean changes in liver fat fraction. Results: Mean change in three-dimensional volumetric liver fat fraction between Months 0 and 18 was +2.89% (95% CI: +.89%, +4.88%) among participants with cured HCV and +0.48% (95% CI: -1.02%, +1.97%) among controls (between group difference Conclusions: Three-dimensional volumetric liver fat fraction by MRI significantly increased between Months 0 and 18 following successful treatment of HCV infection, but this finding was not observed from Month 0 to 18 among participants without HCV infection.

Indexed as

hepatic steatosishepatitis Cliver fat fractionmagnetic resonance imaging

Identifiers

PMID42819228
PMCPMC13625188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.